BioSpace News Archive

CymaBay Therapeutics, Inc., a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, announced that two-year safety and efficacy results of seladelpar for primary biliary cholangitis have been published in Alimentary Pharmacology & Therapeutics.

vTv Therapeutics Inc. announced that it has entered into a common stock repurchase agreement with Reneo Pharmaceuticals, Inc. through which Reneo has purchased all of its common stock that was granted to vTv under the Reneo License Agreement for total proceeds to vTv of approximately $4.4 million.

Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will release its financial results for the third quarter ended September 30, 2023 and provide an update on the company on Tuesday, November 14, 2023.

Ocular Therapeutix, Inc. (NASDAQ:OCUL) today announced it had received written agreement regarding the overall design from the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for the Company’s ongoing pivotal Phase 3 clinical trial for AXPAXLI (axitinib intravitreal implant), for the treatment of wet age-related macular degeneration (wet AMD), which the Company refers to as the SOL trial.

The Stupid Strong Charitable Foundation is proud to announce a significant commitment of $450,000 in grant funding over four years to support a groundbreaking research project at The University of Texas MD Anderson Cancer Center.

INOVIO today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan.

Aptatek BioSciences, Inc. has appointed Drawbridge Health Chairperson Lee McCracken as a non-executive director.

Quantum-Si Incorporated today announced that it will be participating in two upcoming investor conferences.

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Sam Raha as Chief Operating Officer (COO), effective December 11, 2023.

Lexicon Pharmaceuticals, Inc. announced that Express Scripts, the pharmacy benefits management business of The Cigna Group’s Evernorth, has determined that it will place INPEFA on its Basic and High Performance formularies for commercially insured patients as of, November 1, 2023, and in addition to the previously reported Premier Access and Premier Performance national formularies for Medicare patients.